UniProtKB/Swiss-Prot P29965 : Variant p.Ala208Asp
CD40 ligand
Gene: CD40LG
Feedback ?
Variant information
Variant position:
208
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Alanine (A) to Aspartate (D) at position 208 (A208D, p.Ala208Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and hydrophobic (A) to medium size and acidic (D)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In HIGM1; decreases ITGA5:ITGB1 and ITGAV:ITGB3 binding of the soluble form; decreases activation of NF-kappa-B signaling.
Any additional useful information about the variant.
Sequence information
Variant position:
208
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
261
The length of the canonical sequence.
Location on the sequence:
PFIASLCLKSPGRFERILLR
A ANTHSSAKPCGQQSIHLGGV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PFIASLCLKSPGRFERILLRA ANTHSSAK-PCGQQSIHLGGV
PFVASLCLHSPSGTERVLLRA ASSRGSSK-PCGQQSIHLGG
Rhesus macaque PFIASLCLKSPGRFERILLRA ANTHSSAK-PCGQQSIHLGG
Mouse PFIVGLWLKPSSGSERILLKA ANTHSSSQ-LCEQQSVHLGG
Rat PFIVSLWLKPSSGSERILLRA ANTHSSSK-LCEQQSIHLGG
Pig PFIASLCLRSPSGSERILLRA ANTHSSSK-PCGQQSIHLGG
Bovine PFIASLCLKSPSGSERILLRA ANTHSSSK-PCGQQSIHLGG
Cat PFIASLCLHSPSGSERVLLRA ANARSSSK-PCGQQSIHLGG
Chicken PFTLYIYLYLPMEEDRLLMKG LDTHSTSTALCELQSIREGG
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 261
CD40 ligand, membrane form
Chain
113 – 261
CD40 ligand, soluble form
Topological domain
47 – 261
Extracellular
Domain
122 – 261
THD
Disulfide bond
178 – 218
Mutagenesis
224 – 224
H -> E. Decreases ITGA5:ITGB1 binding, B-cell activation, activation of NF-kappa-B signaling, and anti-apoptotic signaling; when associated with E-226 in soluble form. No effect on CD40 binding; when associated with E-226 in soluble form.
Mutagenesis
226 – 226
G -> E. Decreases ITGA5:ITGB1 binding, B-cell activation, activation of NF-kappa-B signaling, and anti-apoptotic signaling; when associated with E-224 in soluble form. No effect on CD40 binding; when associated with E-224 in soluble form.
Beta strand
203 – 210
Literature citations
Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling.
Takada Y.K.; Yu J.; Shimoda M.; Takada Y.;
J. Immunol. 203:1383-1391(2019)
Cited for: FUNCTION AS CD40 AND INTEGRIN LIGAND; CHARACTERIZATION OF VARIANTS HIGM1 CYS-170; ARG-174; ILE-176; ASP-208; TYR-224; ALA-226; VAL-227 AND SER-258; MUTAGENESIS OF TYR-170; HIS-224; GLY-226 AND GLY-252;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.